Achillion Takeover Looms as Hepatitis Treatments Fail

Achillion Takeover Looms as Hepatitis Treatments Fail

David Paul Morris/Bloomberg

The biggest deal was Gilead’s $10.8 billion acquisition of Pharmasset Inc., announced in November.